Clinical Trial

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Name: A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 — clinical trial record (NCT07546760)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2026-04-16; most recent amendment 2026-07-03.

Trial Details

NCT Number	NCT07546760
Lead Sponsor	AstraZeneca
Conditions	Hepatic Impairment
Enrollment	28 participants
Start Date	2026-03-20
Primary Completion	2027-02-04 (estimated)
Study Completion	2027-02-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-04